🔗 Share this article Social Media Influencers Driving Parallel Trade for Unlicensed Slimming Medication A shadow market for unlicensed slimming medications is being driven by social media fitness personalities and sellers on messaging platforms, according to new investigations. Experimental Drug Gaining Popularity Online The experimental drug, which remains in clinical trials, is being advertised by social media influencers for its alleged weight-reducing properties. Followers are encouraged to message these profiles privately for supplier links, while also obtaining promotional offers. Thriving Trade on Social Networks Additionally, a flourishing market exists on messaging services, where groups with thousands of participants share comparison photos, administration instructions and assertions of rapid British shipping. Vendors promote the substance there before redirecting customers to WhatsApp for transactions. Understanding The Experimental Drug This medication is an investigational injection developed by US drugmaker Eli Lilly. The treatment targets three gut hormones – GLP-1, GIP and glucagon. Preliminary studies suggest it could help individuals lose up to a quarter of their body weight. Nicknamed the “triple G”, the substance is being hailed digitally as the next Ozempic. Medical Experts Voice Worries However, doctors and pharmacists have cautions that the sale of what is still an unapproved medication in the UK is a cause for concern and could result in users injecting substances of unknown origin. Some experts said the popularity for retatrutide could be connected to the rising cost of licensed weight loss products such as Mounjaro. Legal Position and Enforcement Selling retatrutide on social media or Telegram is illegal in the UK, as it is an unlicensed medication that must not be marketed or supplied for personal consumption under the Human Medicines Regulations 2012. Several content creators try to sidestep the regulations by referring to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted substance, but advertising and distribution can still breach medicines, marketing, and customer regulations, potentially leading to penalties, prosecution or prison. Platform Response and Content Removal According to TikTok, the service has removed problematic material and banned related keywords and query recommendations. The organization said it was committed to maintaining the service secure and investing in enhancing enforcement strategies. Digital Marketplace Operations Investigations also found groups with up to nine thousand participants marketing retatrutide using the platform's built-in search feature, which operates like a online catalog. Typing “retatrutide” instantly displays channels with numerous of users, populated with images of weight loss, positive testimonials and step-by-step guides for mixing or injecting at home. Within minutes of joining one group, a vendor shared WhatsApp details, where the majority of purchases take place. The seller sent an instruction manual and guaranteed delivery within 48 hours. When asked whether the product was genuine, one seller responded: “You can’t be sure.” Another shared a photo of a alleged laboratory certificate. Not one inquired about weight, medical conditions or previous experience. Item Information and Costs Inside these groups, messages show dark colored packages with postal service labels, stating to include fresh supplies. One message stated: “It took eight of us to load them this morning.” Buyers can select between powder vials, mixed at residence with purified liquid, or ready-to-use pens typically priced at £160 for 20mg. When asked how long a pen should be used, vendors give conflicting responses varying between a few weeks to “depends on your body”. Service Oversight and Security Actions A representative for the messaging service stated it actively monitored harmful material on its service including material that promoted the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”. Medical Professional Warnings “Individuals are administering materials they can’t verify. Even if the research behind retatrutide is valid, these digital versions may not contain what they advertise,” said a pharmacy expert, the head of pharmaceutical services at a pharmacy service. Dr Crystal Wyllie of Asda Online Doctor connected the surge in demand to current price rises for authorized weight-loss drugs such as Mounjaro. “With costs rising, individuals are using social media. But counterfeit injections are highly risky. You can’t be certain what’s inside or whether the environment they were produced in was clean,” she explained. Her team has already seen patients harmed by self-injection from unconfirmed sources. “We understand the disappointment, but buying from messaging apps or communication platforms is taking chances with your well-being,” stated the doctor. “These substances could be impure or incorrectly dosed.” Producer Statement A spokesperson from Eli Lilly said the substance was in third stage research studies and had not been evaluated or approved by any government authority anywhere in the world. “Consequently at this point no one can market [it] for personal consumption,” they explained, adding that any product “misleadingly claiming itself as a Lilly investigational substance not yet approved … may subject users to possibly serious medical dangers”.